JRCT ID: jRCT2080225260
Registered date:02/07/2020
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 25/07/2020 |
Target sample size | 960 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : High Dose Aflibercept Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Aflibercept Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | safety efficacy pharmacokinetics |
Key inclusion & exclusion criteria
Age minimum | >= 50age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04423718,JapicCTI-205356 |
Contact
Public contact | |
Name | |
Address | |
Telephone | - |
byl_ct_contact@bayer.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | - |
byl_ct_contact@bayer.com | |
Affiliation |